August 2021: VBS Literature Update
Fang, Y et al. Development of macular atrophy after pars plana vitrectomy for myopic traction maculopathy and macular hole retinal detachment in pathologic myopia. Retina. 2020;40(10):1881-93. DOI: 10.1097/IAE.0000000000002709.
Abstract by Musa Abdelaziz, MD
Development of Macular Atrophy After Pars Plana Vitrectomy for Myopic Traction Maculopathy and Macular Hole Retinal Detachment in Pathologic Myopia
Pathologic myopia (PM) is the major cause of legal blindness worldwide. The most serious lesion associated with severe vision loss in PM is the development of macular atrophy (MA). Prior studies have noted the development of fovea-involved MA soon after pars plana vitrectomy (PPV). The aim of this study was to determine the clinical features of eyes with PM that developed MA after PPV.
This was a retrospective study of 133 eyes of 126 patients with high myopia that had undergone PPV for myopic traction maculopathy (MTM). High myopia was defined as spherical equivalent of < -8.0 diopters or an axial length ≥ 26.5 mm. All patients underwent 25-gauge PPV and internal limiting membrane (ILM) peeling with the assistance of indocyanine green (ICG). Cataract surgery was performed concurrently in all phakic eyes. Three different ILM peeling procedures were used: complete ILM peeling, fovea-sparing ILM peeling (FSIP), and inverted ILM flap (IIF). A tamponade of air, sulfur hexafluoride (SF6), octafluoropropane (C3F8), or silicone oil was placed after the peel with prone positioning ranging from 1 day to 2 weeks. Eyes with previous macular buckle, history of choroidal neovascularization, or had laser photocoagulation near the macula were excluded.
A total of 133 eyes of 126 patients (94 women and 32 men) were included. The mean age was 62.8 years and mean axial length was 30.0 mm. The mean preoperative BCVA was 20/63 and mean follow-up was 39.3 months. The preoperative foveal status as determined by optical coherence tomography (OCT) as:
- Macular retinoschisis (MRS) only in 30 eyes (22.4%)
- MRS and foveal retinal detachment (fRD) in 45 eyes (33.6%)
- Full-thickness macular hole (FTMH) in 38 eyes (28.4%)
- Macular hole retinal detachment (MHRD) in 20 eyes (15.0%)
Characteristics of eyes with MA after PPV: 14 of the 133 eyes (10.5%) developed fovea-centered MA and the preoperative status of the MTM was:
| Preoperative status | Eyes with MA after PPV | Prevalence of MA after PPV |
| MRS | 1 | 3.3% |
| MRS and fRD | 2 | 4.4% |
| FTMH | 5 | 13.2% |
| MHRD | 6 | 30% |
| ILM Peel (# eyes) | Eyes with MA after PPV | Prevalence of MA after PPV |
| No ILM peeling (5) | 0 | 0.0% |
| FSIP (42) | 1 | 2.4% |
| Complete (82) | 12 | 14.6% |
| IIF (4) | 1 | 25% |
MA after PPV typically develops at the center of the fovea and expands around the fovea at a median time of 3.5 months after PPV. The eyes that developed MA had preoperative MHRD more frequently and had worse final BCVA than those without (20/100 versus 20/50). The 3 eyes that developed MA without FTMH had inner lamellar macular hole (ILMH). The prevalence of MA after PPV was higher in eyes that underwent complete ILM peeling compared to FSIP.
The results show that MA develops in 10.5% of high myopia eyes with MTM after PPV, and the presence of MHRD was associated with the highest risk of developing MA. In eyes with MHRD, it is thought the longstanding subretinal fluid can be harmful to exposed retinal pigment epithelium. The high prevalence of MA in eyes with FTMH or MHRD could be a result of ICG toxicity. However, that would not explain the MA that developed in the 3 eyes with inner lamellar macular hole (ILMH). It is possible ICG may have reached the retinal pigment epithelium during surgery in the ILMH eyes by the formation of a small FTMH during ILM peeling as these eyes underwent complete ILM peeling. There are a few limitations to the study given the retrospective nature and the use of ICG. It would be interesting to see a future that uses a dye with less retinal toxicity (e.g. brilliant blue G) and assess the prevalence of MA based on surgical technique.
Overview
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Identify the preoperative optical coherence tomography of myopic traction maculopathy with highest risk of developing macular atrophy after vitrectomy
Accreditation
Provided by Evolve Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC and Vit Buckle Society. Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures

Musa Abdelaziz, MD
Retina Center of Texas
Plano, TXDISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.The following faculty/staff members have the following financial relationships with commercial interests:
Musa Abdelaziz, MD, has no financial relationships with commercial interests.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Vit Buckle Society.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!












